Clinical Utility of Blood Natriuretic Peptide Levels

Login or register to view PDF.
Citation
US Cardiology 2006;2005:2(1):1-8

Pages

Heart failure (HF) is a common condition and carries a considerable age-dependent all-cause mortality.1 As a leading cause of hospitalization in adults, ~50% of patients discharged with a diagnosis of HF are readmitted within six months, and the one-year mortality rate is 20% after an initial diagnosis is established. There is currently a chronic HF epidemic with a rapidly expanding prevalence pool of HF patients, which has accounted for increased rates of hospitalization over the past two decades.1-3 Accordingly, much effort has been directed toward understanding the pathophysiology of HF, as well as improving diagnostic and therapeutic strategies. The recognition of the natriuretic peptides, in particular B-type natriuretic peptide (BNP), as a marker for the diagnosis, prognosis, and severity of HF has been a major breakthrough.4 This article will focus on the latest advances in the clinical utility of BNP in a variety of applications (see Figure 1).

Natriuretic PeptidesÔÇöImportant 'Heart HormonesÔÇÖ

There are three major natriuretic peptides, all sharing a common 17-amino-acid ring structureÔÇöatrial natriuretic peptide, BNP, and C-type natriuretic peptide.5 B-type natriuretic peptide is synthesized and stored in the ventricular myocardium as a precursor prohormone. Cleavage of the 32 amino acid sequence by the enzyme corin from the C-terminal end of ProBNP results in the active BNP peptide hormone and the inactive N-terminal fragment of proBNP (NT-proBNP). B-type natriuretic peptide is secreted into the circulation in a pulsatile fashion through the coronary sinuses in response to left ventricular (LV) wall stretch and multiple neurohumoral factors. It has a half-life of 22 minutes and is metabolized by neutral endopeptidase (~30%), and receptor-mediated endocytosis (~70%), which occurs predominantly in the kidney. Normally, BNP levels are slightly higher in women compared with men.6 Additionally, in the obese, BNP levels are 30% to 50% lower than those of normal body weight, either because of impaired BNP production or increased peripheral clearance of BNP.6 Both BNP and NT-proBNP have been found in urine. NT-proBNP is not cleared by neutral endopeptidase or by the clearance receptors, hence its clearance is more dependent on glomerular filtration with incomplete resorption, resulting in considerable quantities found in the urine.7 These urinary levels are high enough to be used as a urinary test for HF.7

Pages

References
  1. McCullough P A, Philbin E F, Spertus J A, Kaatz S, Sandberg K R,Weaver W D,Confirmation of a Heart Failure Epidemic: Findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study, J.Am. Coll. Cardiol. (2002);39: pp. 60-69.
    Crossref | PubMed
  2. American Heart Association, Heart disease and stroke statistics-2003 update, accessed December 1 2003, available at: www.americanheart.org
  3. Jessup M, Brozena S,Heart Failure,N. Engl. J. Med. (2003);348: pp. 2,007-2,018.
    Crossref
  4. McCullough P A, B-type natriuretic peptides. A diagnostic breakthrough in heart failure, Minerva Cardioangiol. (April 2003);51(2): pp. 121-129.
    Crossref | PubMed
  5. Maisel A S, McCullough P A,Cardiac natriuretic peptides: A proteomic window to cardiac function and clinical management, Rev. Cardiovasc. Med. (2003);4(suppl. 4):S3-S12.
    PubMed
  6. McCullough P A, Sandberg K R, Sorting out the evidence on natriuretic peptides, Rev. Cardiovasc. Med. (2003);4 suppl. 4:S13-19.
    PubMed
  7. Ng L L, Loke I W, Davies J E, Geeranavar S, Khunti K, Stone M A, Chin D T, Squire I B,Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides, J.Am. Coll. Cardiol. (April 2005);5;45(7): pp. 1,043-1,050.
    Crossref | PubMed
  8. McCullough P A, Sandberg K R, Sorting out the evidence on natriuretic peptides, Rev. Cardiovasc. Med. (2003);4(suppl. 4):S13-S19.
    PubMed
  9. McDonagh T A, Robb S D, Murdoch D R et al.,Biochemical detection of left-ventricular systolic dysfunction, Lancet (January 3 1998);351(9095): pp. 9-13.
    Crossref | PubMed
  10. Vasan R S, Benjamin E J, Larson M G, Leip E P,Wang T J,Wilson P W, Levy D, Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study, JAMA (September 11 2002);11;288(10): pp. 1,252-1,259.
    Crossref | PubMed
  11. Wang T J, Larson M G, Levy D, Benjamin E J, Leip E P, Omland T,Wolf P A,Vasan R S, Plasma natriuretic peptide levels and the risk of cardiovascular events and death,N. Engl. J. Med. (February 12 2004);350(7): pp. 655-663.
    Crossref | PubMed
  12. McCullough P A, Khandelwal A K, McKinnon J E et al.,Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America, Congest. Heart Fail. (January-February 2005);11(1): pp. 6-11.
    Crossref
  13. Maisel A S, Krishnaswamy P, Nowak R M, McCord J, Hollander J E et al., Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure,N. Engl. J. Med. (2002);347: pp. 161-167.
    Crossref | PubMed
  14. McCullough P A, Nowak R M, McCord J, Hollander J E, Herrmann H C et al., B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure. Analysis from Breathing Not Properly Multinational Study (BNPMS), Circulation (2002);106: pp. 416-422.
    Crossref
  15. Silver M A, Maisel A,Yancy C W et al., BNP Consensus Panel, BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases, Congest Heart Fail. (September-October 2004);10(5 suppl. 3): pp. 1-30.
    Crossref | PubMed
  16. McCullough P A, Duc P, Omland T, McCord J, Nowak R M, Hollander J E, Herrmann H C, B-type natriuretic peptide and renal function in the diagnosis of heart failure:An analysis from the Breathing Not Properly Multinational Study,Am.J. Kidney Dis. (2003);41: pp. 571-579.
    Crossref | PubMed
  17. Lubien E, DeMaria A, Krishnaswamy P et al., Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with doppler velocity recordings, Circulation (2002);105: pp. 595-601
    Crossref | PubMed
  18. Maisel A S, McCord J, Nowak R M et al., Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction, J.Am. Coll. Cardiol. (2003);41: pp. 2,010-2,017.
    Crossref | PubMed
  19. Koglin J, Pehlivanli S, Schwaiblmair M,Vogeser M, Cremer P,Von Scheidt W,Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure, J.Am. Coll. Cardiol. (2001);38: pp. 1,934-1,941.
    Crossref | PubMed
  20. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R, B-type natriuretic peptide predicts sudden death in patients with chronic heart failure, Circulation (2002);105: pp. 2,392-2,397.
    Crossref | PubMed
  21. Gallagher M J, McCullough P A,The emerging role of natriuretic peptides in the diagnosis and treatment of decompensated heart failure, Curr. Heart Fail. Rep. (September 2004);1(3): pp. 129-135.
    Crossref | PubMed
  22. Horwich T B, Patel J, MacLellan R, Fonarow G C, Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure, Circulation (2003);108: pp. 833-838.
    Crossref | PubMed
  23. Bettencourt P, Ferreira S,Azevedo A, Ferreira A,Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure, Am. J. Med. (2002);113: pp. 215-219.
    Crossref | PubMed
  24. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A, A rapid bedside test for Btype peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study, J.Am. Coll. Cardiol. (2001);37: pp. 386-391.
    Crossref
  25. Logeart D,Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC,Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure, J.Am. Coll. Cardiol. (February 18 2004);43(4): pp. 635-641.
    Crossref | PubMed
  26. Anand I S, Fisher L D, Chiang Y T et al.,Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT), Circulation (2003);107: pp. 1,278-1,283.
    Crossref | PubMed
  27. Mueller C, Scholer A, Laule-Kilian K et al., Use of B-type nariuretic peptide in the evaluation and management of acute dyspnea, N. Engl. J. Med. (2004);350: pp. 647-654.
    Crossref | PubMed
  28. Luther S A, McCullough P A, Havranek E P et al., for the Cardiovascular Outcomes Research Consortium,The Relationship Between B-type Natriuretic Peptide and Health Status in Patients With Heart Failure, J. Card. Fail. (August 2005);11(6): pp. 414-421.
    Crossref | PubMed
  29. Troughton R W, Frampton C M,Yandle T G, Espiner E A, Nicholls M G, Richards A M,Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations, Lancet (2000);355: pp. 1,126-1,130.
    Crossref | PubMed
  30. Inomata T, Nishii M,Takehana H et al.,Brain natriuretic peptide-guided treatment reduces cardiovascular events of heart failure in outpatient management, Circulation (2003);(108)17;IV446 (2053 abstract).
  31. Jourdain P, Funck F, Gueffet P et al., for the French Working Group on Heart Failure, Benefit of BNP plasma levels for optimizing therapy:The Systolic Heart Failure Treatment Supported by BNP Multicenter Randomised Trial (STARS-BNP), J.Am. Coll. Cardiol. (2005): pp. 1,001-1,151; 3A(abstract).
  32. de Lemos J A, Morrow D A, Bentley J H et al.,The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes, N. Engl. J. Med. (2001);345: pp. 1,014-1,021.
    Crossref | PubMed
  33. Morrow D A, de Lemos J A, Sabatine M S et al., Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18, J.Am. Coll. Cardiol. (April 16 2003);41(8): pp. 1,264-1,272.
    Crossref | PubMed
  34. Deo R, de Lemos J A,B-type natriuretic peptide in ischemic heart disease,Curr. Cardiol.Rep. (July 2003);5(4): pp. 271-277.
    Crossref | PubMed
  35. ten Wolde M,Tulevski II, Mulder J W, Sohne M, Boomsma F, Mulder B J, Buller H R,Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism, Circulation (April 29 2003);107(16): pp. 2,082-2,084, E-pub (April 21 2003).
    Crossref | PubMed
  36. Kruger S, Graf J, Merx M W, Koch K C, Kunz D, Hanrath P, Janssens U,Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism, Am. Heart J. (January 2004);147(1): pp. 60-65.
    Crossref | PubMed
  37. Charpentier J, Luyt C E, Fulla Y et al.Brain natriuretic peptide:A marker of myocardial dysfunction and prognosis during severe sepsis, Crit. Care Med. (March 2004);32(3): pp. 660-665.
    Crossref | PubMed
  38. McCullough P A, Steg P G, Aumont MC et al., BNP Multinational Study Investigators. What Causes Elevated B-Type Natriuretic Peptide in Patients Without Heart Failure?, J.Am. Coll. Cardiol. (2003);41:278A
    Crossref
  39. Berendes E, Schmidt C,Van Aken H et al., A-type and B-type natriuretic peptides in cardiac surgical procedures, Anesth. Analg. (January 2004);98(1): pp. 11-19, table of contents.
    Crossref | PubMed
  40. Wazni O M, Martin D O, Marrouche N F et al.,Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery, Circulation (July 13 2004);110(2): pp. 124-127.
    Crossref | PubMed
  41. Hutfless R, Kazanegra R, Madani M et al., Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery, J.Am. Coll. Cardiol. (May 19 2004);43(10): pp. 1,873-1,879.
    Crossref | PubMed
  42. Chello M, Mastroroberto P, Perticone F, Cirillo F, Bevacqua E, Olivito S, Covino E,Plasma levels of atrial and brain natriuretic peptides as indicators of recovery of left ventricular systolic function after coronary artery bypass, Eur. J. Cardiothorac. Surg. (July 2001);20(1): pp. 140-146.
    Crossref | PubMed
  43. Gerber I L, Stewart R A, Legget M E et al.,Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis, Circulation (April 15 2003);107(14): pp. 1,884-1,890.
    Crossref | PubMed
  44. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjornerheim R, Endresen K, Hall C, Natriuretic peptides in patients with aortic stenosis, Am. Heart J. (October 2001);142(4): pp. 725-732.
    Crossref | PubMed
  45. Bergler-Klein J, Klaar U, Heger M et al.,Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis, Circulation (May 18 2004);109(19): pp. 2,302-2,308, E-pub (April 26 2004).
    Crossref | PubMed
  46. Gerber I L, Stewart R A, French J K et al.,Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation, Am. J. Cardiol. (September 15 2003);92(6): pp. 755-758, erratum in: Am. J. Cardiol. (February 15 2004);93(4): p. 526.
    Crossref | PubMed
  47. Sutton T M, Stewart R A, Gerber I L,West T M, Richards A M,Yandle T G, Kerr A J,Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation, J.Am. Coll. Cardiol. (June 18 2003);41(12): pp. 2,280-2,287.
    Crossref | PubMed
  48. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) 2005 by the American College of Cardiology Foundation and the American Heart Association, Inc.